Category: Latest News
-

AI boom is mirroring past speculative cycles and may be nearing its peak, BCA warns
Artificial intelligence is exhibiting the same telltale signs seen in earlier investment bubbles that eventually collapsed, according to a new analysis from BCA Research, which cautions that the current surge could begin to fade within the next year. In a report authored by Peter Berezin, BCA’s chief global strategist, the firm argues that its review…
-

BitMine shares slide after CEO transition and new board appointments
BitMine Immersion Technologies Inc. (AMEX:BMNR) saw its stock fall 4.7% in premarket trading on Friday after unveiling a major leadership overhaul and several additions to its board. The company — which describes itself as the world’s largest ETH Treasury holder with more than 2.9% of the Ethereum network — announced that Chi Tsang has been…
-

Tenon Medical shares edge higher after completing $2.85 million PIPE financing
Tenon Medical Inc. (NASDAQ:TNON) saw its stock climb 3.4% in premarket trading on Friday after the company announced it had formally closed its previously disclosed at-the-market private investment in public equity (PIPE) transaction. The medical device company, which develops solutions for sacro-pelvic conditions, secured roughly $2.85 million in gross proceeds through the sale of 2,217,904…
-

MicroStrategy’s Bitcoin stash appears to shrink by 47,000 coins; Saylor posts “HODL” amid market slump
MicroStrategy’s (NASDAQ:MSTR) Bitcoin reserves have dropped by roughly 47,000 coins, according to new figures published Friday by crypto analytics firm Arkham. Arkham’s data shows that the company’s holdings have fallen to about 437,000 Bitcoin, down from a previously reported 484,000. It remains unclear whether the apparent decline reflects internal transfers or whether any coins were…
-

Walmart appoints John Furner as next CEO, succeeding Doug McMillon in 2026
Walmart Inc. (NYSE:WMT) announced that its board of directors has chosen John Furner to become the company’s next president and chief executive officer, with his appointment set to take effect on February 1, 2026. Furner, 51, will take over from longtime CEO Doug McMillon, 59, who plans to retire on January 31, 2026. Alongside the…
-

Anavex shares collapse after CHMP issues negative signal on Alzheimer’s therapy
Anavex Life Sciences Corp. (NASDAQ:AVXL) saw its stock plunge by 50% on Friday after revealing that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) delivered a negative trend vote on its Alzheimer’s drug candidate, blarcamesine. The company said the CHMP is expected to issue a final opinion on the therapy’s Marketing…
-

Legence stock climbs as strong Q3 revenue marks impressive debut after IPO
Legence Corp. (NASDAQ:LGN) delivered a stronger-than-expected third-quarter report on Friday, posting revenue of $708 million—well above analyst forecasts of $638.93 million—and representing a 26% year-over-year surge in its first earnings release since going public. The engineering and installation services firm reported adjusted EBITDA of $88.8 million, up 39% from the same period last year. Despite…
-

Spire posts wider-than-expected Q4 loss, revenue falls short of estimates
Spire Inc. (NYSE:SR) reported a deeper adjusted loss in its fiscal fourth quarter, posting -$0.47 per share compared with analyst expectations of -$0.43. Quarterly revenue totaled $334.1 million, significantly below the consensus estimate of $422.84 million. For fiscal year 2025, Spire generated adjusted earnings of $4.44 per share, a 7.5% improvement from $4.13 in 2024.…
-

Avadel shares jump after receiving higher $23-per-share takeover proposal
Avadel Pharmaceuticals plc (NASDAQ:AVDL) surged 16% on Friday after announcing that it had received an unexpected acquisition proposal from H. Lundbeck A/S, valuing the company at up to $23.00 per ordinary share. Lundbeck’s bid includes $21.00 per share in cash at closing, along with a non-transferable contingent value right (CVR) that could deliver up to…
-

Bristol Myers Squibb shares slide after halting key heart trial
Bristol Myers Squibb (NYSE:BMY) dropped 5.2% in premarket trading on Friday after the pharmaceutical company said it would stop its Phase 3 Librexia ACS study of milvexian in patients with acute coronary syndrome. The move comes after a planned interim review by the Independent Data Monitoring Committee, which concluded the study was unlikely to achieve…